While CD37 is predominantly being examined for dual targeting for B cell malignancies, the expression of CD37 in some cases of CTCL and peripheral T cell lymphoma (PTCL) makes it an attractive target in these malignancies, otherwise difficult to treat with CAR-T cell-based therapies. This evidence concerns the gene CD37 and primary cutaneous T-cell non-Hodgkin lymphoma.